The Receives $14 Million in Strategic Funding to Bolster U.S. Pharmaceutical Independence
Summary
The decrease in U.S.-based production for APIs and key starting materials (KSMs) used to make them is widely recognized as a major driver behind this significant national health security risk. By focusing on developing these high-impact molecules, we are creating a private-public blueprint for driving self-reliance that is essential for national health security and can be replicated across the country, said Tony Sardella, chair and founder of APIIC.This project harnesses the strengths of APIICs extensive partner network, including collaborations with leading universities, pharmaceutical manufacturers, and suppliers of KSMs. These strategic collaborations form a dynamic product team, capitalizing on each members specific expertise, with APIIC providing funding and support to harness their strengths and advanced manufacturing capabilities.Mallinckrodt Specialty Generics is proud to partner with the API Innovation Center on this critical initiative to bolster the U.S. pharmaceutical supply chain. We are excited to bring our 25 years of CDMO expertise in organic synthesis and bioconjugation of ADCs, producing Active Pharmaceutical Ingredients (API), excipients and critical raw materials, to this partnership. UMSL is proud to play a key role in advancing these critical efforts, which will have lasting impacts on both our regions economy and the nations health security, said Dr. Chris Spilling, vice chancellor for research and economic and community development at the University of Missouri-St. Louis.APIIC, together with the State of Missouri and the Missouri Technology Corporation, has been developing a state-supported model in the St. Louis region and a strategic framework for creating a resilient national pharmaceutical manufacturing ecosystem.